10x Genomics (TXG) Debt to Equity (2018 - 2019)
10x Genomics' (TXG) quarterly Debt to Equity came in at $0.07 in Q4 2019, up 152.44% year-on-year from $0.03 in Q4 2018, and little changed quarter-over-quarter from $0.07 in Q3 2019.
10x Genomics (TXG) Debt to Equity (2018 - 2019) Analysis & Trends
10x Genomics has disclosed Debt to Equity across 2 years of filings, most recently posting $0.07 for Q4 2019.
- Debt to Equity for Q4 2019 came in at $0.07, up 152.44% year-over-year; the trailing twelve-month figure through Dec 2019 was $0.07 (up 152.44% YoY), and the FY2019 annual result was $0.07, up 152.44% from the prior year.
- Debt to Equity came in at $0.07 for Q4 2019 at 10x Genomics, roughly flat from $0.07 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $0.07 in Q4 2019 to a low of -$0.13 in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Veeva Systems | 24.83 Bn | 17.52 Bn | 662.02 Mn | - |
| 2 | BrightSpring Health Services | 13.57 Bn | 12.69 Bn | 482.22 Mn | 1.26 |
| 3 | Healthequity | 7.20 Bn | 6.93 Bn | 256.31 Mn | 0.46 |
| 4 | Hinge Health | 5.42 Bn | 5.11 Bn | 154.23 Mn | - |
| 5 | 10x Genomics | 4.46 Bn | 3.92 Bn | 106.18 Mn | - |
| 6 | Doximity | 3.81 Bn | 3.06 Bn | 125.97 Mn | - |
| 7 | Waystar Holding | 3.52 Bn | 3.36 Bn | 268.04 Mn | 0.37 |
| 8 | Privia Health | 2.94 Bn | 2.57 Bn | 595.71 Mn | - |
| 9 | Omnicell | 1.76 Bn | 1.59 Bn | 140.36 Mn | - |
| 10 | Teladoc Health | 1.45 Bn | 696.57 Mn | 562.57 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 0.07 |
| Sep 30, 2019 | 0.07 |
| Dec 31, 2018 | -0.13 |